18F-rhPSMA-7 PET在前列腺癌生化复发中的阳性预测值与正确检出率:复合参考标准验证
这项回顾性研究评估了18F-rhPSMA-7 PET/CT在前列腺癌根治术后生化复发患者中的检出率(DR)、阳性预测值(PPV)和正确检出率(CDR),采用复合参考标准验证。共纳入532例患者(中位PSA 0.97 ng/mL),其中162例有复合随访。结果显示PET的DR为80%,复合队列中PPV为88%、CDR为70%;PSA≥1 ng/mL者CDR达82%,PSA<1 ng/mL者CDR为59%。
要点
- 18F-rhPSMA-7 PET/CT在生化复发患者中检出率80%,复合队列PPV为88%。
- PSA≥1 ng/mL者DR 90%、PPV 91%、CDR 82%;PSA<1 ng/mL者CDR仅59%。
- 检出效能与分层PSA水平(P=0.005)及术后PSA谷值(P<0.001)显著正相关。
核心结论
- 18F-rhPSMA-7 PET/CT在根治术后生化复发中具有高阳性预测值,正确检出率依赖扫描前PSA值,PSA≥1 ng/mL者正确检出率优异。
研究设计与样本
- 回顾性研究,纳入2017年7月至2018年6月间根治术后生化复发并接受18F-rhPSMA-7 PET/CT的患者532例,中位PSA 0.97 ng/mL(四分位距0.41-2.46 ng/mL)。
- 参考标准为组织病理学或组织病理学、影像学或PSA随访的组合,定义为复合参考标准;162例患者有复合随访,中位随访5.6个月(范围1.1-14.2个月)。
- 检出率(DR)为PSMA PET阳性患者占全部患者的比例,正确检出率(CDR)为至少1个真阳性PSMA PET病灶且与参考标准对应的患者百分比,PPV为真阳性患者占所有阳性发现的比例。
主要发现
- 全部患者中PET检出率为80%;复合随访队列中,按患者计算的PPV为88%,CDR为70%。
- 组织病理学验证队列中PPV为91%,CDR为73%。
- PSA≥1 ng/mL患者DR为90%、PPV为91%、CDR为82%;PSA<1 ng/mL患者DR为69%、PPV为85%、CDR为59%。
- 18F-rhPSMA-7 PET/CT检出效能与分层PSA水平呈显著正相关(P=0.005),与根治术后PSA谷值也呈显著正相关(P<0.001)。
- PET/CT未见病灶、局限性疾病和任何远处转移(M1)的患者比例分别为20%、43%和37%。
关键数值与推荐
- 复合参考标准定义为组织病理学或组织病理学、影像学或PSA随访的组合。
- PPV在复合队列为88%,组织病理学队列为91%;CDR在复合队列为70%,组织病理学队列为73%。
- PSA≥1 ng/mL者CDR为82%,PSA<1 ng/mL者CDR为59%。
临床怎么用
- 18F-rhPSMA-7 PET/CT可用于根治术后生化复发患者的再分期,阳性结果具有较高阳性预测值。
- 扫描前PSA水平影响正确检出率,PSA≥1 ng/mL时正确检出率较高,PSA<1 ng/mL时正确检出率相对较低。
局限性
- 回顾性研究设计。
- 仅162例患者有复合随访,复合随访中位时间5.6个月(范围1.1-14.2个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The objective of this retrospective study was to assess the detection rate (DR), positive predictive value (PPV), and correct detection rate (CDR) of 18F-rhPSMA-7 PET/CT in biochemical recurrence (BCR) of prostate cancer (PCa) after radical prostatectomy (RP) using composite validation. Methods:18F-rhPSMA-7 PET/CT scans of patients with BCR between July 2017 and June 2018 were retrospectively reviewed. All suspicious lesions were recorded. The reference standard was histopathology or combinations of histopathology, imaging, or prostate-specific antigen (PSA) follow up, defined as composite reference standard. DR was calculated as the proportion of PSMA PET-positive patients to all patients independent of the reference standard, whereas the CDR was the percentage of patients who had at least 1 true-positive PSMA PET lesion localized that corresponded with the reference standard. The PPV was defined as the proportion of patients who had true-positive to all positive findings. The correlation between DR and patient characteristics was evaluated. Results: A total of 532 patients with a median PSA level of 0.97 ng/mL (interquartile range: 0.41-2.46 ng/mL) were included. Of these, 162 patients had composite follow-up at a median duration of 5.6 mo (range: 1.1-14.2 mo). The proportion of patients who had no lesion visualized on PET/CT, localized disease, and any distant metastases (M1) were 20%, 43%, and 37%, respectively. PET DR among all patients was 80%. On a per-patient basis, the PPV of 18F-rhPSMA-7 PET/CT in the composite cohort was 88%, and the CDR was 70%. The PPV in the histopathology-proven cohort was 91%, and the CDR in this subgroup was 73%. In patients with PSA levels ≥ 1 ng/mL the DR and PPV were 90% and 91%, respectively, resulting in a CDR of 82%. In patients with PSA levels < 1 ng/mL, the DR and PPV were 69% and 85%, respectively, resulting in a CDR of 59%. There was a significant positive correlation between 18F-rhPSMA-7 PET/CT detection efficacy and stratified PSA levels (P = 0.005), as well as PSA nadir after prostatectomy (P < 0.001). Conclusion:18F-rhPSMA-7 PET/CT offers high PPV in BCR after RP. Its CDR is dependent on the prescan PSA value with excellent CDR in patients with PSA ≥ 1 ng/mL.
引用
- Chantadisai M, Buschner G, Krönke M, et al. Positive Predictive Value and Correct Detection Rate of 18F-rhPSMA-7 PET in Biochemically Recurrent Prostate Cancer Validated by Composite Reference Standard. J Nucl Med. 2020. PMID: 33188151. doi:10.2967/jnumed.120.255661
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。